Anti-Obesity Pill Wins Approval

Source: Associated Press (7/17/12)

"Vivus Inc.'s Qsymia is the second weight-loss drug approved by the FDA in less than a month, following Arena Pharmaceutical's pill Belviq in late June."

Associated Press

A new weight-loss pill that many doctors consider the most effective of a new generation of anti-obesity drugs got the approval of the U.S. Food and Drug Administration on Tuesday.

The pill, called Qsymia, was approved for patients who are overweight or obese and also have at least one weight-related condition such as high blood pressure, diabetes or high cholesterol.

The drug offers hope for those who have failed to lose weight in other ways, but its path to approval also underscores how difficult it has been for drugmakers to find obesity treatments that are safe and effective.

The drug's maker, Vivus Inc., said it plans to bring the drug to market in the fourth quarter of this year. It hasn't yet decided what the pills will cost. . .View Full Article

Clean-Tech Co. Looks Forward to Massive Market Breakthroughs in 2026
Source: Streetwise Reports (12/31/2025)

BioLargo Inc.'s (BLGO:OTCQX) President and Chief Executive Officer Dennis P. Calvert notes the company is looking forward to its part in "what may be one of the largest infrastructure and technology investment cycles in history."

Clean-Tech Firm Anticipates Major Market Advancements in 2026
Source: Streetwise Reports (12/30/2025)

Dennis P. Calvert, President and CEO of BioLargo Inc. (BLGO:OTCQX), mentions that the company is eager to participate in "what may be one of the largest infrastructure and technology investment cycles in history."

Mineral Investor Chen Lin Argues Silver Moving From Bullion to Physical Asset, Reveals Picks
Source: Streetwise Reports (12/16/2025)

Seasoned minerals investor Chen Lin argues silver's 50-year breakout is not a routine cycle but a transition from bullion to a tightening "critical minerals" market. Read on to see what some of his top picks are, including one biotech company he thinks could be the next Eli Lilly.

Market Experts Uncover Excellent Buys During December 'Silly Season' Tax Selloff
Source: Streetwise Reports (12/15/2025)

Every December, tax-loss selling tends to exert downward pressure on certain stocks as investors aim to offset capital gains. Streetwise Reports asked some of its frequent contributors to add their own thoughts on the other "holiday season" and give their own picks for good bargains.

Data on 2 Drugs, Identified Via AI, Shared at Conference
Source: Dr. Douglas Loe (12/04/2025)

Rakovina Therapeutics Inc.'s (RKV:TSX.V) preclinical ATR inhibitors, Compound A and Compound C, exhibit similarities to two clinical-stage drugs in the same class, noted a Leede Financial Inc. report.